Erratum for the Research Article: “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study” by P. Kiessling, R. Lledo-Garcia, S. Watanabe, G. Langdon, D. Tran, M. Bari, L. Christodoulou, E. Jones, G. Price, B. Smith, F. Brennan, I. White, S. Jolles

See allHide authors and affiliations

Science Translational Medicine  06 Dec 2017:
Vol. 9, Issue 419, eaar6448
DOI: 10.1126/scitranslmed.aar6448

Log in to view full text

Log in through your institution

Log in through your institution

Navigate This Article